Amneal Pharmaceuticals, Inc. beat EPS estimates 88% of the time across 16 reported quarters (14 beats, 2 misses), averaging +34.2% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $0.24 | $0.27 | +12.5% | Beat | |
| Q1 FY26 | $0.25 | $0.25 | +0.0% | Beat | Q1 FY26 call |
| Q4 FY25 | $0.17 | $0.19 | +11.8% | Beat | |
| Q3 FY25 | $0.12 | $0.15 | +25.0% | Beat | |
| Q2 FY25 | $0.17 | $0.23 | +35.3% | Beat | |
| Q1 FY25 | $0.14 | $0.19 | +35.7% | Beat | |
| Q4 FY24 | $0.13 | $0.10 | -23.1% | Miss | |
| Q3 FY24 | $0.12 | $0.15 | +25.0% | Beat | |
| Q2 FY24 | $0.11 | $0.15 | +36.4% | Beat | |
| Q1 FY24 | $0.08 | $0.12 | +50.0% | Beat | |
| Q4 FY23 | $0.05 | $0.12 | +140.0% | Beat | |
| Q3 FY23 | $0.10 | $0.17 | +70.0% | Beat |
Back to AMRX overview · AMRX holders · AMRX KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.